NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K Filing
NeOnc Technologies reports increased objective response rate in NEO100 Phase 2a study to 12.5% following additional patient response. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $NTHI
Read the full article at SEC EDGAR
Part of the story NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K Filing (3 articles)